吉西他滨联合奥沙利铂治疗中晚期原发性肝癌的临床对照研究  

An initial study of GEMOX regimen for the patients with advanced hepatocellular carcinoma

作　　者：彭春雷[1] 徐爱兵[1] 苏小琴[1] 

机构地区：[1]江苏省南通市肿瘤医院,通州226361

出　　处：《南通大学学报（医学版）》2008年第4期281-283,共3页Journal of Nantong University(Medical sciences)

摘　　要：目的:观察吉西他滨联合奥沙利铂治疗晚期原发性肝癌的有效性及安全性。方法:50例晚期原发性肝癌患者随机分为两组,观察组27例采用吉西他滨联合奥沙利铂组成的GEMOX方案进行治疗,对照组23例采用单药吉西他滨,分别以RECIST标准和NCICTC标准观察和评价其疗效和毒性。结果:观察组的疾病控制率为63.0%,而对照组的疾病控制率为39.1%,两组差异有统计学意义(P<0.05)。两组最常见的毒副反应为骨髓毒性,以中性粒细胞和血小板下降为主;其次为消化道反应,以恶心、呕吐多见;观察组的毒副反应较对照组无明显增加。结论:吉西他滨联合奥沙利铂组成的GEMOX方案静脉化疗对于原发性肝癌的疗效优于单药组,且安全性高,不良反应较轻,患者易耐受,值得进一步临床试用。Objective:To observe the efficiency and safety of gemeitabin combined with oxaliplatin in treating the patients with histologically confirmed recurrent,metastatic,or unresectable hepatocenular carcinoma.Methods:After signing informed consent,50 patients were randomly divided into the treatment group and the control group.27 patients of the treatment group with advanced hepatoceUular carcinoma were treated with the combination of Gemcitabine and oxaliplatin (GEMOX regimen). And the other 23 patients of the c...

关 键 词：原发性肝癌 吉西他滨 奥沙利铂 联合化疗 

分 类 号：R735.7[医药卫生—肿瘤]